SF
CHRS icon

Summit Financial’s Coherus Oncology CHRS Stock Holding History

Summit Financial’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Buy
114,861
+2,773
+2% +$4.53K ﹤0.01% 1546
2026
Q1 		$189K Buy
+112,088
New +$199K ﹤0.01% 1358

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Summit Financial's CHRS Position: Q2 2026 in Review

Summit Financial increased its Coherus Oncology (CHRS) stake by 2.5% in Q2 2026, buying an estimated $4.53K and bringing the position to 114,861 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #1546.

Summit Financial first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $189K in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Summit Financial held 114,861 shares of Coherus Oncology worth $161K as of Q2 2026.
  • Summit Financial bought 2,773 Coherus Oncology shares in Q2 2026, an estimated $4.53K.
  • Coherus Oncology made up ﹤0.01% of Summit Financial's portfolio in Q2 2026, its #1546 holding.
  • Summit Financial first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Summit Financial's Coherus Oncology position peaked at $189K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.